Serina Therapeutics, Inc.
SER
$1.77
-$0.13-6.84%
AMEX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | 100.00% | -- | 154.90% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 100.00% | -- | 154.90% | -- |
| Cost of Revenue | 8.40% | 43.81% | 51.18% | 97.74% | 166.82% |
| Gross Profit | -8.40% | -42.96% | -52.06% | -95.85% | -168.03% |
| SG&A Expenses | 5.99% | 65.64% | -5.84% | 9.47% | 138.28% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.20% | 52.92% | 20.02% | 45.39% | 151.85% |
| Operating Income | -7.20% | -52.39% | -20.33% | -43.95% | -152.39% |
| Income Before Tax | -42.91% | -20.57% | -432.25% | -224.82% | 67.89% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -43.05% | -21.22% | -432.25% | -224.82% | 67.89% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -100.00% | -62.96% | -48.15% | -- |
| Net Income | -43.32% | -21.75% | -425.18% | -223.90% | 67.95% |
| EBIT | -7.20% | -52.39% | -20.33% | -43.95% | -152.39% |
| EBITDA | -7.21% | -53.92% | -21.31% | -45.68% | -154.40% |
| EPS Basic | -16.08% | -5.22% | -384.49% | -207.36% | 90.83% |
| Normalized Basic EPS | 11.14% | -125.64% | -374.88% | -204.98% | 82.81% |
| EPS Diluted | -17.58% | -5.52% | -448.62% | -229.41% | 90.83% |
| Normalized Diluted EPS | 11.14% | -125.64% | -433.90% | -225.25% | 82.81% |
| Average Basic Shares Outstanding | 23.48% | 17.01% | 16.81% | 17.50% | 249.68% |
| Average Diluted Shares Outstanding | 23.48% | 17.01% | -3.83% | -1.51% | 249.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |